Quintrio
Home

PHARMACEUTICAL PREPARATIONS

OnKure Therapeutics, Inc. Class A Common Stock

OKUR

OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3Kα. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.

Last trade $2.53
Day change -$0.225 (-8.18%)
Day range $2.48 – $2.82
Volume 143,769
Market cap $113M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$113.27M
Price / earnings
—
Price / book
0.72×
Price / sales
—
EV / sales
—
EV / EBITDA
0.58×

Profitability

Earnings per share
-$1.50
Return on assets
-37.02%
Return on equity
-39.21%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
18.84×
Quick ratio
18.84×
Cash ratio
17.23×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$47.94M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for OKUR, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$4.29M$4.29M$3.91M$3.41M$3.59M$3.71M$3.99M$4.34M
Research and development$15.06M$12.61M$11.71M$10.72M$11.92M$12.61M$13.01M$14.36M
Total operating expenses$19.35M$16.9M$15.62M$14.13M$15.5M$16.32M$17M$18.7M
Operating income-$19.35M-$16.9M-$15.62M-$14.13M-$15.5M-$16.32M-$17M-$18.7M
Interest expense$0$0$0-$6K-$2K$0$0-$57K
Income before taxes-$17.85M-$15.35M-$15.16M-$13.5M-$14.7M-$15.39M-$15.93M-$17.44M
Income taxes$0$0$0$0$0$0$0$0
Net income-$17.85M-$15.35M-$15.16M-$13.5M-$14.7M-$15.39M-$15.93M-$17.44M
Net income attributable to common shareholders-$17.85M-$15.35M-$15.16M-$13.5M-$14.7M-$15.39M-$15.93M-$17.44M
EBITDA-$19.3M-$16.81M-$15.51M-$14.02M-$15.39M-$16.21M-$16.88M-$18.58M
Basic earnings per share-$0.36-$0.31-$1.11-$0.99-$1.09-$1.14-$1.19-$1.36
Diluted earnings per share-$0.36-$0.31-$1.11-$0.99-$1.09-$1.14-$1.19-$1.36

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference

OnKure Therapeutics announced that senior management will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14-16, 2026, in New York. The company will host one-on-one investor meetings during the event. OnKure is advancing IND-enabling activities for next-generation PI3Kα inhibitor candidates OKI-345 and OKI-355, with IND submissions planned for the first half of 2027.

GlobeNewswire Inc.

OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026

OnKure Therapeutics announced a virtual key opinion leader event on July 15, 2026, featuring prominent researchers to discuss the company's PI3Kα inhibitor drug candidates. The company is advancing two next-generation PI3Kα pan-mutant inhibitor programs (OKI-345 for breast cancer and OKI-355 for vascular anomalies) with plans to submit IND applications to the FDA in the first half of 2027.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.